Baker Bros. Advisors LP 13D and 13G filings for Aerovate Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 4:21 pm Sale | 2024-09-30 | 13G | Aerovate Therapeutics, Inc. AVTE | Baker Bros. Advisors LP | 628,939 2.200% | -1,051,578 (-62.57%) | Filing |
| 2024-02-14 4:21 pm Sale | 2023-12-31 | 13G | Aerovate Therapeutics, Inc. AVTE | Baker Bros. Advisors LP | 1,680,517 6.100% | -296,351 (-14.99%) | Filing |
| 2023-02-14 4:00 pm Purchase | 2022-12-31 | 13G | Aerovate Therapeutics, Inc. AVTE | Baker Bros. Advisors LP | 1,976,868 8.000% | 145,079 (+7.92%) | Filing |
| 2022-02-14 4:14 pm Purchase | 2021-12-31 | 13G | Aerovate Therapeutics, Inc. AVTE | Baker Bros. Advisors LP | 1,831,789 7.500% | 1,831,789 (New Position) | Filing |